Literature DB >> 8804940

Interleukin-1 receptor antagonist in pleural effusion due to inflammatory and malignant lung disease.

H Yanagawa1, S Yano, T Haku, Y Ohmoto, S Sone.   

Abstract

Interleukin (IL)-1 is a key cytokine in inflammatory reactions. To clarify the mechanism of inflammation in the pleural cavity, we investigated the contribution of IL-1 and its antagonism to inflammatory processes in the pleural cavity. Interleukin-1 receptor antagonist (IL-1Ra) levels as well as IL-1 beta and interferon-gamma (IFN-gamma) levels were measured by enzyme immunoassay in pleural effusions from 70 patients. Pleural macrophages were also examined as possible sources of these cytokines in 10 patients. IL-1Ra was detectable in 28 patients (40%) out of 70 patients with pleural effusions. Patients with tuberculosis had significantly higher IL-1Ra as well as IFN-gamma levels in pleural effusion than patients with lung cancer. Transudative pleural effusions had low or undetectable IL-IRa levels. On the other hand, IL-1 beta levels were low, except in cases of parapneumonic pleural effusion. Spontaneous production of IL-1Ra pleural macrophages was observed in six patients, and IL-4 significantly augmented its production. Although spontaneous production of IL-1 beta was observed in only two patients, pleural macrophages produced significant amounts of IL-1 beta in response to lipopolysaccharide in all 10 patients examined. These results suggest that interleukin-1 receptor antagonist regulates various reactions by interleukin-1 in pleural effusion, and that pleural macrophages may act in situ as a source of interleukin-1 receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8804940     DOI: 10.1183/09031936.96.09061211

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  4 in total

1.  Epithelial to mesenchymal transition of mesothelial cells in tuberculous pleurisy.

Authors:  Changhwan Kim; Dong-Gyu Kim; Sung-Hoon Park; Yong Il Hwang; Seung Hun Jang; Cheol Hong Kim; Ki-Suck Jung; Kwangseon Min; Jae Woong Lee; Young Sook Jang
Journal:  Yonsei Med J       Date:  2011-01       Impact factor: 2.759

2.  Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods.

Authors:  Zhenyu Xie; Xin Li; Yuzhen He; Song Wu; Shiyue Wang; Jianjian Sun; Yuchen He; Yu Lun; Shijie Xin; Jian Zhang
Journal:  BMC Cancer       Date:  2020-11-25       Impact factor: 4.430

3.  The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer.

Authors:  D J McKeown; D J F Brown; A Kelly; A M Wallace; D C McMillan
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

4.  Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.

Authors:  Erminia Massarelli; Amir Onn; Edith M Marom; Christine M Alden; Diane D Liu; Hai T Tran; Barbara Mino; Ignacio I Wistuba; Saadia A Faiz; Lara Bashoura; George A Eapen; Rodolfo C Morice; J Jack Lee; Waun K Hong; Roy S Herbst; Carlos A Jimenez
Journal:  Clin Lung Cancer       Date:  2014-05-14       Impact factor: 4.785

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.